Fortune recently published its 2023 list of the largest corporations in the U.S. ranked by revenue for their respective 2022 fiscal years. The Fortune 500 list includes 80 healthcare companies. Among those, eight are in the top 25 of the ROL100 Ranking, which uses publicly available information to assess Return on Leadership scores for the top 100 companies on the latest Fortune 500 list, according to the publication.
For the ROL100 ranking, Fortune partnered with Indiggo. The ranking assessed organizations' "capacity for execution through its leaders and managers" based on connection to purpose, strategic clarity, leadership alignment, and focused action.
Fortune said a mix of three to five key indicators is assessed for each of the four drivers to determine the overall Return on Leadership score and ranking for each company. More information about the methodology is available here.
The eight healthcare companies that cracked the top 25 of the ROL100:
Thermo Fisher Scientific (No. 4 in ROL100 ranking)
Pfizer (No. 5 in ROL100 ranking)
HCA Healthcare (No. 8 in ROL100 ranking)
Elevance Health (No. 9 in ROL100 ranking)
UnitedHealth Group (No. 11 in ROL100 ranking)
Merck (No. 15 in ROL100 ranking)
Humana (No. 18 in ROL100 ranking)
Bristol-Myers Squibb (No. 24 in the ROL100 ranking)